4//SEC Filing
TALLARIGO LORENZO 4
Accession 0001144204-12-064361
CIK 0001270073other
Filed
Nov 19, 7:00 PM ET
Accepted
Nov 20, 9:16 PM ET
Size
9.5 KB
Accession
0001144204-12-064361
Insider Transaction Report
Form 4
TALLARIGO LORENZO
Director
Transactions
- Award
Options to Purchase Common Stock
2012-11-16+4,673→ 4,673 totalExercise: $21.50Exp: 2022-11-16→ Common Stock (4,673 underlying) - Award
Restricted Stock Units
2012-11-16+2,942→ 2,942 total→ Common Stock (2,942 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
- [F2]The vesting of all stock options and restricted stock units granted to Dr. Tallarigo has been suspended until October 10, 2013, at which time all such stock options and restricted stock units that would have vested as of such date will vest and all remaining unvested stock options and restricted stock units will continue vesting in accordance with the original terms of the grant (the "Vesting Suspension").
- [F3]Pursuant to the original vesting terms of the grant, the shares underlying the restricted stock units are deemed to vest on a pro rata basis from August 9, 2012 (the "Vesting Start Date") until August 9, 2014 on each three month anniversary of the Vesting Start Date. The original terms of the grant provide that 25.0% of the shares underlying the restricted stock units, representing the shares that would have vested on each three month anniversary of the Vesting Start Date through February 9, 2013, will vest on April 9, 2013, and the remainder of the shares originally underlying the restricted stock units will vest pro rata on each subsequent three month anniversary of the Vesting Start Date starting from May 9, 2013 through August 9, 2014, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). These vesting provisions have been suspended until October 10, 2013 pursuant to the Vesting Suspension.
- [F4]The original terms of the grant provide that 12.5% of the shares underlying this option vested as of November 16, 2012, the date of grant, and the remainder of the shares underlying this option will vest pro rata on a monthly basis starting from December 9, 2012 through August 9, 2014, subject to the terms and conditions of the award and the 2012 Plan. These vesting provisions have been suspended until October 10, 2013 pursuant to the Vesting Suspension.
- [F5]Not applicable.
Documents
Issuer
INTERCEPT PHARMACEUTICALS INC
CIK 0001270073
Entity typeother
Related Parties
1- filerCIK 0001276039
Filing Metadata
- Form type
- 4
- Filed
- Nov 19, 7:00 PM ET
- Accepted
- Nov 20, 9:16 PM ET
- Size
- 9.5 KB